231 related articles for article (PubMed ID: 28413162)
1. Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.
Seim I; Jeffery PL; Thomas PB; Nelson CC; Chopin LK
G3 (Bethesda); 2017 Jun; 7(6):1731-1741. PubMed ID: 28413162
[TBL] [Abstract][Full Text] [Related]
2. Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
Sienkiewicz K; Yang C; Paschal BM; Ratan A
Prostate; 2022 Mar; 82(4):442-451. PubMed ID: 34951700
[TBL] [Abstract][Full Text] [Related]
3. Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing.
Kang M; Cho E; Jang J; Lee J; Jeon Y; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Investig Clin Urol; 2019 Jul; 60(4):227-234. PubMed ID: 31294131
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
[TBL] [Abstract][Full Text] [Related]
5. Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6.
Schmitt J; Noble A; Otsuka M; Berry P; Maitland NJ; Rumsby MG
Br J Cancer; 2014 Oct; 111(8):1646-56. PubMed ID: 25137020
[TBL] [Abstract][Full Text] [Related]
6. Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole-Genome Sequencing.
Pham MT; Gupta A; Gupta H; Vaghasia A; Skaist A; Garrison MA; Coulter JB; Haffner MC; Zheng SL; Xu J; DeStefano Shields C; Isaacs WB; Wheelan SJ; Nelson WG; Yegnasubramanian S
Mol Cancer Res; 2022 Jul; 20(7):1013-1020. PubMed ID: 35452513
[TBL] [Abstract][Full Text] [Related]
7. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
8. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines.
Hermans KG; van Alewijk DC; Veltman JA; van Weerden W; van Kessel AG; Trapman J
Genes Chromosomes Cancer; 2004 Mar; 39(3):171-84. PubMed ID: 14732919
[TBL] [Abstract][Full Text] [Related]
9. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
[TBL] [Abstract][Full Text] [Related]
10. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Jarrard DF; Bova GS; Ewing CM; Pin SS; Nguyen SH; Baylin SB; Cairns P; Sidransky D; Herman JG; Isaacs WB
Genes Chromosomes Cancer; 1997 Jun; 19(2):90-6. PubMed ID: 9171999
[TBL] [Abstract][Full Text] [Related]
11. Next generation mapping reveals novel large genomic rearrangements in prostate cancer.
Jaratlerdsiri W; Chan EKF; Petersen DC; Yang C; Croucher PI; Bornman MSR; Sheth P; Hayes VM
Oncotarget; 2017 Apr; 8(14):23588-23602. PubMed ID: 28423598
[TBL] [Abstract][Full Text] [Related]
12. Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer.
Jaratlerdsiri W; Chan EKF; Gong T; Petersen DC; Kalsbeek AMF; Venter PA; Stricker PD; Bornman MSR; Hayes VM
Cancer Res; 2018 Dec; 78(24):6736-6746. PubMed ID: 30217929
[TBL] [Abstract][Full Text] [Related]
13. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
[TBL] [Abstract][Full Text] [Related]
14. An EP4 antagonist ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer.
Xu S; Zhang Z; Ogawa O; Yoshikawa T; Sakamoto H; Shibasaki N; Goto T; Wang L; Terada N
Cell Biochem Biophys; 2014 Sep; 70(1):521-7. PubMed ID: 24744183
[TBL] [Abstract][Full Text] [Related]
15. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
16. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Quigley DA; Dang HX; Zhao SG; Lloyd P; Aggarwal R; Alumkal JJ; Foye A; Kothari V; Perry MD; Bailey AM; Playdle D; Barnard TJ; Zhang L; Zhang J; Youngren JF; Cieslik MP; Parolia A; Beer TM; Thomas G; Chi KN; Gleave M; Lack NA; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Ryan CJ; Fong L; Kim W; Friedlander T; Chou J; Li H; Das R; Li H; Moussavi-Baygi R; Goodarzi H; Gilbert LA; Lara PN; Evans CP; Goldstein TC; Stuart JM; Tomlins SA; Spratt DE; Cheetham RK; Cheng DT; Farh K; Gehring JS; Hakenberg J; Liao A; Febbo PG; Shon J; Sickler B; Batzoglou S; Knudsen KE; He HH; Huang J; Wyatt AW; Dehm SM; Ashworth A; Chinnaiyan AM; Maher CA; Small EJ; Feng FY
Cell; 2018 Jul; 174(3):758-769.e9. PubMed ID: 30033370
[TBL] [Abstract][Full Text] [Related]
17. Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.
Kamradt J; Jung V; Wahrheit K; Tolosi L; Rahnenfuehrer J; Schilling M; Walker R; Davis S; Stoeckle M; Meltzer P; Wullich B
PLoS One; 2007 Aug; 2(8):e769. PubMed ID: 17712417
[TBL] [Abstract][Full Text] [Related]
18. p53 oncogene mutations in three human prostate cancer cell lines.
Carroll AG; Voeller HJ; Sugars L; Gelmann EP
Prostate; 1993; 23(2):123-34. PubMed ID: 8104329
[TBL] [Abstract][Full Text] [Related]
19. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.
Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS
Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982
[TBL] [Abstract][Full Text] [Related]
20. Genetic abnormalities specifically associated with varying metastatic potential of prostate cancer cell lines as detected by comparative genomic hybridization.
Chu LW; Pettaway CA; Liang JC
Cancer Genet Cytogenet; 2001 Jun; 127(2):161-7. PubMed ID: 11425457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
